Skip to main content
. 2021 Feb 15;7(3):454–466. doi: 10.1021/acscentsci.0c01237

Figure 5.

Figure 5

N-Trifluoroethyl alkylation and lipidation of 2-liraglutide performs as well as liraglutide at lowering blood sugar levels in vivo. (a) Measured glucose levels by tail vein prick for an oral glucose tolerance test (OGTT) of fasted mice treated intraperitoneally (i.p., dotted line) with vehicle, GLP1, 2-GLP1, 7-GLP1, liraglutide, or 2-liraglutide at (1 mg/kg or 0.1 mg/kg as noted). Glucose bolus was administered orally at time 0 and 240 min (gray, upward arrow). (b) Average area under the curve (AUC) calculated from 0 to 120 min in part a. (c) Glucose levels 30 min past second glucose challenge that occurred 5 h after first OGTT. Error represents the average ± SEM (n = 5). P-values compared to vehicle: **P < 0.01; ***P < 0.001; ****P < 0.0001.